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Abstract: Adaptation to import iron for proliferation makes cancer cells potentially sensitive to iron
toxicity. Iron loading impairs multiple myeloma (MM) cell proliferation and increases the efficacy of
the proteasome inhibitor bortezomib. Here, we defined the mechanisms of iron toxicity in MM.1S,
U266, H929, and OPM-2 MM cell lines, and validated this strategy in preclinical studies using Vk*MYC
mice as MM model. High-dose ferric ammonium citrate triggered cell death in all cell lines tested,
increasing malondialdehyde levels, the by-product of lipid peroxidation and index of ferroptosis.
In addition, iron exposure caused dose-dependent accumulation of polyubiquitinated proteins in
highly iron-sensitive MM.1S and H929 cells, suggesting that proteasome workload contributes to iron
sensitivity. Accordingly, high iron concentrations inhibited the proteasomal chymotrypsin-like activity
of 26S particles and of MM cellular extracts in vitro. In all MM cells, bortezomib-iron combination
induced persistent lipid damage, exacerbated bortezomib-induced polyubiquitinated proteins
accumulation, and triggered cell death more efficiently than individual treatments. In Vk*MYC mice,
addition of iron dextran or ferric carboxymaltose to the bortezomib-melphalan-prednisone (VMP)
regimen increased the therapeutic response and prolonged remission without causing evident toxicity.
We conclude that iron loading interferes both with redox and protein homeostasis, a property that
can be exploited to design novel combination strategies including iron supplementation, to increase
the efficacy of current MM therapies.
Keywords: multiple myeloma; iron; ferroptosis; proteasome
1. Introduction
Cancer cells rearrange iron trafficking proteins to promote iron uptake and retention, to favor
proliferation [1,2]. Accordingly, iron chelation has been proposed as a strategy to impair tumor
growth [3,4]. The opposite holds true, since excess iron is toxic, even for cancer cells, because it
catalyzes oxidative stress. Cellular defensive machinery against iron excess relies on increasing
translation of the safe-iron storage protein ferritin, promoting degradation of the iron importer
transferrin receptor 1 (TFR1) to inhibit further iron uptake and enhancing ferroportin protein on cell
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surface to favor iron export [5,6]. Notwithstanding this coordinated response, exposure to iron excess
increases the cytosolic iron pool, oxidative stress, and consequent cell damage [7].
We have recently demonstrated the efficacy of exploiting iron toxicity to affect cancer cells growth
in models of multiple myeloma (MM), a disease in which malignant plasma cells accumulate in the bone
marrow and secrete monoclonal immunoglobulin, generating bone disease, organ failure and anemia [8].
Iron exposure triggers reactive oxygen species (ROS) formation, promoting cell death, impairing MM
cell proliferation in vitro and disease expansion in vivo [9]. We also found that the proteasome inhibitor
bortezomib, a compound commonly used in the setting of MM patients, impairs the physiologic
response to iron excess, i.e., TFR1 degradation and ferritin increase, abolishing the cellular defensive
response against iron exposure and maximizing the toxicity of supplemented iron [10]. Accordingly,
bortezomib-iron combination impairs MM cell viability and disease expansion more efficiently than
individual agent treatments [9,10], suggesting that the addition of high-dose iron to bortezomib-based
pharmacological schedules is worth being explored to increase their therapeutic efficacy.
Iron is involved in multiple cellular processes and dysregulation of its homeostasis potentially
interferes with several pro-survival adaptive mechanisms that occur in MM cells, including the
maintenance of protein homeostasis. Exploring the role of iron in the latter process is particularly
promising, considering our previous findings on additive effect of iron toxicity and proteasome
inhibition. Protein homeostasis is finely tuned in MM cells in order to support high production
of immunoglobulins through the secretory pathway [11,12]. MM cells must efficiently degrade
misfolded immunoglobulins and protein aggregates to protect themselves from proteotoxic stress [13].
Abnormal proteins degradation occurs in a ubiquitin-dependent manner by the proteasome system,
making the proteasome vulnerable in MM cells [14] and providing the rationale for the efficacy of
proteasome inhibitors, such as bortezomib and carfilzomib, drugs that have significantly improved
MM patient outcome. In this context, low proteasome capacity and high proteasome workload identify
proteasome-inhibitor sensitive cells [15]. Autophagy contributes to proteostasis in MM: high basal
levels of autophagy are essential for MM cell survival [16] and provide an alternative proteolytic
pathway in response to proteotoxic stress induced by proteasome inhibition. Accordingly, accumulation
of misfolded proteins by proteasome inhibition stimulates autophagy, an event that contributes to
bortezomib resistance in some MM cells, such as U266 cells [17].
Based on our findings that iron excess negatively affects MM cell growth and that combination
of iron with bortezomib increases treatment efficacy, here we investigated the mechanisms of iron
toxicity. We studied the effect of iron excess on redox and protein homeostasis in MM cell lines whose
iron sensitivity was previously validated, as the MM.1S and U266 cells [9], and in two additional cell
lines, the H929 and OPM-2 cells, never tested before. Then, we proved the translational relevance of
our findings by testing the effect of iron on carfilzomib efficacy and by adding high-dose iron to the
common bortezomib-melphalan-prednisone (VMP) regimen in a preclinical study using the Vk*MYC
mice as MM model [18].
2. Results
2.1. Iron Causes Lipid Damage and Impairs Proteasome Functionality in MM Cell Lines
We treated MM.1S, U266, H929 and OPM-2 cell lines with high iron concentration (600 µM ferric
ammonium citrate, FeAC) or 10 nM bortezomib or FeAC plus bortezomib for 24 h. As an iron source,
we utilized ferric iron (FeAC) that is commonly used for in vitro experiments with cells since it is
stable at neutral pH and converted to bioactive ferrous iron inside the cells. In all cell lines, iron and
bortezomib caused cell death, and their combination was more effective than treatment with single
agents (Figure 1a and Figure S1A). U266 and OPM-2 appeared less sensitive to iron toxicity than MM.1S
and H929. Treatment extension up to 48 h in the former cells did not exacerbate the effect of iron on
cell viability, while it intensified bortezomib toxicity and the result of bortezomib-iron combination
(Figure 1a and Figure S1A). In all cell lines analyzed at 24 h after treatment, iron strongly increased
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the levels of malondialdehyde (MDA), a by-product of lipid peroxidation and a recognized index of
ferroptosis (Figure 1b and Figure S1B). In accordance with this observation, pre-treatment of U266
cells with 100 µM ferrostatin, a compound that prevents lipid peroxidation, abolished iron-induced
MDA formation and iron toxicity (Figure 1c). Bortezomib had no evident effect on lipid peroxidation,
while bortezomib-iron combination induced MDA formation above levels produced by iron alone in
all cell lines (Figure 1b and Figure S1B). MDA formation was attenuated in U266 and OPM-2 cells
treated with iron as a single agent for 48 h (Figure 1b and Figure S1B). Differently, lipid peroxidation
was strongly enhanced upon bortezomib-iron combination (Figure 1b and Figure S1B). We concluded
that iron exposure triggers cell death by inducing lipid damage and that this event is more evident and
persistent after bortezomib treatment.
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Figure 1. Iron triggers cell death by inducing lipid damage. (a,b) MM.1S and U266 cell lines were
subjected to 600 µM ferric ammonium citrate (FeAC) or 10 nM bortezomib (Btz) or combination for 24 or
48 h. (a) Percentage of dead cells. (b) Malondialdehyde (MDA) levels presented as fold change relative
to untreated cells. (c) Percentage of cell death and MDA levels in U266 cells treated or not with 100 µM
ferrostatin (Fer-1) 2 h before 600 µM FeAC for 24 h. All samples were additionally supplemented with
0.1% DMSO. (a–c) Values are shown as mean ± standard errors of at least 4 independent experiments for
each cell line. Statistical differences were determined by Tukey post-ANOVA test. ns: non-statistically
significant. * p < 0.05; ** p < 0.01. *** p < 0.001.
Then, we investigated whether iron directly interferes with bortezomib activity by mechanistically
exploring the effect of iron on proteasome activity. We carried out a biochemical study by using
highly purified rabbit 26S proteasome that was pre-incubated with ferrous chloride or ferrous
sulfate, at concentrations ranging from 20 µM to 400 µM, or with respective control anions. Ferrous
iron recapitulates the bioactive iron-species that strongly increase within cells after iron exposure.
Both ferrous iron formulations induced a dose-dependent inhibition of chymotrypsin-like activity,
indicating that high iron concentration directly impairs proteasome functionality (Figure 2a and Figure
S2A). The effect of iron was reversible since the dilution of iron after pre-incubation completely restored
proteasome activity (Figure 2b and Figure S2B). Then, we evaluated the effect of iron on the whole
chymotrypsin-like proteasomal activity of MM cell lines by pre-treating cellular extracts with 200 µM
or 400 µM ferrous iron sources. In samples from all cell lines analyzed, both ferrous chloride and
ferrous sulfate significantly inhibited proteasomal chymotrypsin-like activity in a dose-dependent
Cancers 2020, 12, 970 4 of 15
manner (Figure 2c and Figure S2C). Therefore, we concluded that iron loading inhibits proteasome
activity in MM cells.Cancers 2020, 12, x FOR PEER REVIEW 4 of 15 
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Figure 2. Iron impairs proteasomal activity and causes polyubiquitinated proteins accumulation.
(a,b) Evaluation of chymotrypsin-like (C-L) activity of purified 26S proteasome after pre-incubation
with titrated doses of ferrous chloride (FeCl2) for 5 min. (a) Data show the percentage of C-L activity
inhibition. (b) Data show residual C-L activity after pre-incubation with 400 µM FeCl2 followed or not
by iron dilution prior to C-L activity evaluation. (c) Evaluation of proteasomal C-L activity of multiple
myeloma (MM) cellular extracts after pre-incubation with titrated doses of FeCl2 for 5 min. Background
activity (caused by non-proteasomal degradation) was determined by addition of 2 µM epoxomicin
and subtracted from total C-L activity. (d,e) Polyubiquitinated (Poly-Ub) proteins levels in: (d) MM.1S
and U266 cells treated with titrated doses of ferric ammonium citrate (FeAC) for 24 or 72 h; (e) MM cells
treated with 600 µM FeAC or 10 nM bortezomib (Btz) or combination for 6 h (MM.1S) or 48 h (U266);
(f) U266 cells treated with 600 µM FeAC or 0.5 µM MG132 or combination for 48 h. Upper panels:
summary of densitometry of at least 3 independent experiments (Fold relative to untreated). Lower
panels: Representative western blotting. Values are shown as mean ± standard errors. (a–c) Statistical
differences were determined by nonparametric Mann-Whitney U test. (d–f) Statistical differences
were determined by Tukey post-ANOVA test. ns: non-statistically significant. * p < 0.05; ** p < 0.01.
*** p < 0.001.
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To test whether proteasome impairment may occur in iron-exposed cells, we evaluated
poly-ubiquitinated (poly-Ub) proteins levels in MM cell lines treated with titrated doses of FeAC (100,
300 and 600 µM) for 24 and 72 h. Iron caused poly-Ub protein accumulation in a dose-dependent
manner in MM.1S and H929, the effect being detectable at 24 h and exacerbated by treatment extension
(Figure 2d and Figure S2D). Poly-Ub accumulation was barely visible in U266 and OPM-2 cells (Figure 2d
and Figure S2D). In parallel, we evaluated poly-Ub proteins levels in MM.1S and U266 cells treated with
FeAC (600 µM) or bortezomib (10 nM) or combination, as described above. As expected, bortezomib
caused poly-Ub proteins accumulation in both cell lines, confirming the proteasome impairment
(Figure 2e). Addition of iron to bortezomib further increased poly-Ub proteins accumulation in both
cell lines (Figure 2e). A similar result was obtained by treating U266 cells with FeAC (600 µM) and the
proteasome inhibitor MG132 (0.5 µM) (Figure 2f). Altogether our results uncover that iron directly
impairs proteasome functionality, an effect that adds to that of proteasome inhibitors.
Next, we investigated whether iron interferes with the molecular pathways of autophagy by
measuring the levels of microtubule-associated protein 1 light chain 3 (LC3) variants, LC3-I and LC3-II
in representative cell lines. We treated MM.1S and U266 cells with titrated concentrations of FeAC
for 24 or 72 h, in the presence or absence of bafilomycin that blocks autophagosome fusion with
lysosomes. To evaluate autophagosome formation, we measured protein levels and LC3-II/LC3-I
ratio in bafilomycin treated cells. To quantify autophagosome-lysosome fusion rate (autophagic flux),
we considered lysosome LC3-II consumption by measuring the difference of LC3-II levels between
bafilomycin treated and untreated cells. Untreated cells showed low LC3-II levels that were strongly
increased in bafilomycin treated cells, suggesting high rate of LC3-II consumption and autophagic
flux (Figure 3a,b). Treatment with iron for 24 h did not influence LC3 levels, nor LC3-II consumption
(not shown). After 72 h, iron promoted a dose-dependent increase of both LC3-I and LC3-II proteins,
increase of LC3-II/I ratio and of LC3-II consumption by lysosomes in MM.1S (Figure 3a) but not in U266
cells (Figure 3b). We concluded that prolonged iron exposure increases autophagosome formation and
autophagic flux in MM.1S likely as a consequence of poly-Ub proteins accumulation.
Since autophagy upregulation is a compensatory mechanism that contrasts bortezomib
toxicity [16,17], we asked whether stimulation of autophagy by iron might occur upon combination with
bortezomib, partially buffering iron toxicity. We analyzed LC3 levels in U266 cells treated with 600 µM
iron or 10 nM bortezomib or combination for 48 h in presence or absence of bafilomycin. As expected,
addition of bafilomycin that blocks autophagy increased bortezomib and bortezomib-iron toxicity
(Figure S3). As for LC3 dynamics, bortezomib strongly increased LC3-I levels while LC3-II/LC3-I
ratio, LC3-II levels, and LC3-II consumption were reduced compared to bortezomib untreated cells
(Figure 3c). This reduction likely occurred since in bortezomib treated cells the increase of LC3-II
levels and autophagic flux was detectable in insoluble fractions (Figure 3c). Importantly, we did not
appreciate variations between bortezomib and bortezomib-iron treated cells (Figure 3c), excluding
that iron stimulates autophagy more than bortezomib alone. We came to the same conclusion by
considering p62 levels as another autophagy marker. It deeply accumulated in insoluble fractions
upon bortezomib without difference between bortezomib and bortezomib-iron treated cells (Figure 3c).
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Figure 3. Long time iron exposure increases autophagy in MM.1S cells but does not increase autophagy
response after proteasome inhibition. (a,b) LC3 protein levels measured in MM cell lines treated
with titrated doses of ferric ammonium citrate (FeAC) for 72 h. (c) LC3 and p62 protein levels in
soluble and insoluble protein extracts fractions obtained from U266 cells treated with 600 µM FeAC or
10 nM bortezomib (Btz) or combination for 48 h. Where indicated, bafilomycin (BafA1) was added
at 75 nM for the last 8 h of incubation. The rate of autophagosome formation was estimated by
considering LC3-II/LC3-I ratio in bafilomycin treated cells. Autophagic flux was considered as the
difference of LC3-II protein between bafilomycin-treated and untreated cells. Left panels: representative
western blots. Right panels: densitometry summaries of at least 3 independent replicates for each
analysis. Values are shown as mean ± standard errors. Statistical differences were determined by
Tukey post-ANOVA test. ns: non-statistically significant. * p < 0.05; ** p < 0.01. *** p < 0.001. Original
uncropped blots of western blotting showed in Figure S7.
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2.2. Iron Increases Carfilzomib Efficacy in MM Cells
Motivated by translational purpose, we then asked whether iron toxicity increases the efficacy of
carfilzomib, a second-generation proteasome inhibitor recently approved for MM treatment. We treated
MM.1S and U266 cells with 200 µM FeAC or 5 nM carfilzomib or FeAC plus carfilzomib for 24 h.
We reduced iron concentration compared to the experiments described above since here we were mainly
interested in verifying the effect of carfilzomib-iron combination rather than studying the effects of iron
toxicity. As expected, this iron concentration alone was not sufficient to induce cell death in U266 cells,
and carfilzomib caused cell death in both cell lines according to their predicted sensitivity (Figure 4).
Nevertheless, the combination caused more cell death than individual treatments, confirming the
general relevance of the combination of iron toxicity with proteasome inhibition irrespective of the
drug utilized (Figure 4).
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with VMP-Saline after the first cycle (Figure 5B). Based on monoclonal component variation, VMP-
Saline mice relapsed during the following three weeks, while VMP-FeDe mice showed prolonged 
remission (Figure 5C). Subsequent VMP-FeDe cycles successfully controlled the disease expansion, 
whereas VMP-Saline treated mice progressively relapsed, becoming therapy-resistant (Figure 5C). At 
the end of 3 consecutive cycles, VMP-FeDe treated mice showed undetectable monoclonal component 
(Very good response) in 6 out of 11 cases and no case of increased monoclonal component. Differently, 
2 VMP-Saline mice died without experiencing body weight loss before the end of the treatments and 
outlived mice showed undetectable monoclonal component in only 2 out of 9 cases and no response 
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component and PD. In the former mice, PCs were almost undetectable, as in wild-type normal mice, 
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Figure 4. Iron increases carfilzomib efficacy in MM cell lines. Percentage of dead cells measured in
MM.1S and U266 cell lines subjected to 200 µM ferric ammonium citrate (FeAC) or 5 nM carfilzomib
(Cfz) or combination for 24 h. Values are shown as mean ± standard errors of at least 4 independent
experiments for each cell line. Statistical differences were determined by Tukey post-ANOVA test.
ns: non-statistically significant. * p < 0.05; ** p < 0.01. *** p < 0.001.
2.3. Iron Increases the Efficacy of Bortezomib-Melphalan-Prednisone Regimen in Vk*MYC Mice
We previously showed that the bortezomib-iron combination reduces the disease more efficiently
than bortezomib as a ingl agent in MM Vk*MYC mouse model [9]. Here, w further explored th
potentia therapeutic value of this observ tio by testing whether iron addition increases the efficacy of
the VMP regimen. We tr ated VK*MYC mice (Monoclonal component >7%, mea ge 85 ± 14 weeks)
with 3 onsecutive VMP-Saline or VMP-Iron cycles, according t human schedule, using drugs at
human equivalent doses a d iron dextran (FeDe) as iron sou ce (Conversion of Animal Doses to Human
Equivalent Doses, www.fda.gov/medi /72309/download) (Figure 5a). Mice treated w th VMP plus
FeD showed greater reducti n of serum mon clonal component than mice treated with VMP-S line
after the first cycl (Figure 5b). Based on monoclonal compone t vari tion, VMP-Saline mice relaps
during the following thr e weeks, while VMP-FeDe mice sh wed prolonged remission (Figure 5c).
ubs quent VMP-FeDe cycles successfully controlled the disease expansion, whereas VMP-Saline
treated mice progressively relapsed, becoming therapy-resistant (Figure 5c). At t end of 3 consecutive
cycles, VMP-FeDe treated mice showed undetectable mono lonal component (Very good sponse)
in 6 out of 11 cases and no case of incr as d monoclonal componen . Differently, 2 VMP-Sali e
mice died without experiencing body weight l ss before th en of the treatments a d outlived mice
showed und tectable monocl nal compone t in only 2 out of 9 cases and no response or progressive
disease (PD) in the remaining. At sacrifice, we evaluated BM PCs expansion by flow cytometry in
representati ca s from opposite spo se categories, undetectable monoclonal compone t and PD.
In the former mice, PCs were lmost undetectabl , as in wild-type normal mic , wh reas PD mice
showed abundant PCs, confir ing that monoclonal component levels reflect BM isease expansion in
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these VK*MYC cases (Figure S4). We concluded that iron addition is a valuable strategy to increase
VMP regimen efficacy.
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(a) Treatment schedule. Mice were treated with VMP regimen plus/minus 100 mg/Kg iron dextran
(FeDe) for 3 consecutive cycles administered at 7 weeks intervals. Disease expansion was determined
by measuring serum monoclonal component (M-spike) by serum protein electrophoresis (SPE) at
indicated time points. (b) Variation of M-spike levels from treatment start (Day 0) in VMP-Saline (n.11)
and VMP-FeDe (n.11) treated mice at day 21 of the first cycle. Each circle in the scatter graph indicates
M-spike reduction of each mouse analyzed. (c) Variation of M-spike levels from treatment start at
indicated time points during follow-up. Data are shown as means +/- standard errors of M-spike
variation in the 2 treatment groups. (d) M-spike variation at the end of treatment (day 140). Each circle
in the scatter graph indicates M-spike reduction of each mouse analyzed. Two VMP-Saline mice died
during the experiment. Statistically significant differences between VMP-FeDe and VMP-Saline mice
were determined by t-test. * p < 0.05; ** p <0.01.
Since extra iron accumulates in the liver (Figure S5), we measured serum levels of albumin,
cholinesterase and alanine aminotransferase (ALT) as indexes of liver function and hepatocyte necrosis
after 2 cycles and at the end of treatment. All markers remained within reference ranges during the
study in both VMP-Saline and VMP-FeDe treated mice. Similarly, creatinine, a marker of kidney injury,
was unchanged in all conditions (Table 1). We concluded that high-dose parenteral iron did not induce
systemic toxicity in VMP-Iron treated mice.
Table 1. Serum indicators of liver and kidney damage and functionality.
Peripheral
Blood Markers
Treatment Start After Two Cycles End of Treatments ReferencesValues
VMP−Saline VMP−FeDe VMP−Saline VMP−FeDe VMP−Saline VMP−FeDe
lbu in (g/dl) 3.1 ± 0.35 3.1 ± 0.46 3.1 ± 0.26 3.3 ± 0.26 3.0 ± 0.42 2.7 ± 0.36 2.7–3.6
Cholinesterase




51 ± 14 41 ± 13 45 ± 11 46 ± 14 31 ± 6 55 ± 9 <70
Creatinine
(mg/dL) − − − − 0.31 ± 0.03 0.29 ± 0.02 0.31–0.40
To i prove the translational relevance of our findings, in a second set of in vivo experi ents e
replaced iron dextran with ferric carboxy altose (FeC ), a clinically used iron preparation, at lower
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dosage (20 mg/Kg). Although mice of the latter set of experiments displayed a better response to VMP
than mice described above, making challenging the evaluation of the effect of iron by monoclonal
component variation, we observed a trend toward monoclonal component reduction in VMP-FeCM
(p = 0.06 vs VMP-Saline treated mice) (Figure S6A). Considering classes of responses at the end of
the first cycle, VMP-FeCM treated mice showed undetectable monoclonal component in 7 out of
15 cases whereas VMP-Saline treated mice showed undetectable monoclonal component in only 1
out of 12 cases (3 mice died before the first check-point on day 21) (Figure S6A). Toxicity of VMP
treatment became relevant during the follow-up. Eight VMP-Saline mice died without experiencing
body weight loss before the end of the second cycle, for a total of 11 out of 15 mice, making impossible
any comparison with VMP-FeCM mice (Figure S6B). As for the latter, no mouse died during treatment,
and the second VMP-FeCM cycle successfully controlled the disease (Figure S6B). We concluded that
Vk*MYC mice benefit of FeCM addition in terms of both tolerance and response to VMP.
3. Discussion
Based on the finding that MM cells are sensitive to iron toxicity, here we demonstrate that excess
iron has multi-target effects in MM cells and propose that high-dose iron administration can be exploited
for combination therapy to improve the disease control. We investigated the molecular pathways
affected by iron toxicity and whether they interfere with the bortezomib function in four MM cell lines.
Among them, MM.1S and U266 cells are commonly used as models of relatively bortezomib-sensitive
and -resistant MM cells, respectively. We previously showed, and confirm here, that the latter cells
show a similar range of sensitivity when exposed to iron excess [9], suggesting possible interconnection
between the effects induced by iron and proteasome inhibitors.
3.1. Molecular Mechanisms of Iron Toxicity in MM Cells
Toxicity of iron overload is predicted to occur because of iron pro-oxidative properties since excess
iron may react with hydrogen peroxide through the Fenton reaction, generating ROS. Plasma cells are
intrinsically sensitive to iron toxicity because of the continuous production of high levels of hydrogen
peroxide, a byproduct of Ig synthesis and secretion [19–22]. Although malignant transformation is
accompanied by increased iron tolerance for proliferation [1,23], MM cells remain more sensitive to
iron toxicity than other cell types [9].
A number of issues should be considered to explain the entity of iron-induced damage. First,
iron sensitivity depends on ferritin levels, since ferritin safely stores iron, buffering its pro-oxidant
activity [24]. Thus, MM cells with high basal ferritin levels, such as U266, appear equipped to better
counteract iron excess than cells with low basal ferritin levels, as MM.1S [9,10]. Second, iron sensitivity
depends on the efficacy of cell response to iron. Bortezomib interferes with this physiological response
by blocking ferritin increase and TFR1 reduction, maximizing iron toxicity [10]. Finally, the severity of
damage ultimately depends on iron concentration. Thus, treatment with 200 µM FeAC causes cell
death in MM.1S but not in U266 (Figure 4), while 600 µM affects both cell lines (Figure 1a).
Iron exposure increases MDA formation, the final product of polyunsaturated fatty acids
(PUFA) peroxidation and fragmentation. PUFA are highly oxidation-sensitive molecules, and
their peroxidation occurs at a low level in basal growth conditions. This event is physiologically
counteracted by glutathione peroxidase 4 (GPX4), which catalyzes the GSH-dependent reduction
of lipid peroxides [25,26]. When the rate of PUFA peroxidation overcomes cell buffering capacity,
cells undergo death by ferroptosis [25]. Iron is indispensable for this pathway since it catalyzes the
formation of soluble lipid radicals that can initiate and propagate PUFA oxidation and fragmentation.
Accordingly, iron chelation prevents ferroptotic cell death [27]. We found that iron exposure causes
the opposite, overcoming antioxidant machinery, and leading to cell death. As documented in U266
cells, MDA formation occurs early after iron exposure and attenuates with time, probably secondary to
ferritin upregulation. Indeed, combination with bortezomib that blocks ferritin increase prolongs and
intensifies MDA production, exacerbating cell death.
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Adaptation to high-rate lipid peroxidation has an important role in cancer development. Cancer
cells become strongly dependent on GPX4 and on the cystine/glutamate antiporter (system Xc-)
to import extracellular cysteine, essential for GSH biosynthesis [28,29]. Thus, the development of
compounds inducing ferroptosis is emerging as a novel anticancer therapeutic strategy. Erastin,
a system Xc- inhibitor, improves the efficacy of chemotherapy in several cancer cells [30–32]. So far,
only inhibition of the antioxidant system has been explored as a strategy to induce ferroptosis. Here,
we show that ferroptosis can be also induced by altering iron homeostasis, the second arm of lipid
peroxidation rate control, a strategy worth to be explored even beyond MM.
A key finding in MM models is that iron toxicity increases the efficacy of bortezomib, suggesting
that combination with iron supplementation might represent a potential novel strategy to overcome
resistance to proteasome inhibitors. In MM.1S cells, high bortezomib sensitivity has been associated
with low proteasome capacity and constitutive high proteasome workload, while the opposite occurs
in U266, characterized by relatively high proteasome capacity and low workload [15]. We previously
showed that bortezomib, as iron sensitivity, is inversely related to basal ferritin content, since high
ferritin levels, by reducing the free iron pool, probably attenuate the bortezomib pro-oxidant effects
secondary to proteasome inhibition [10]. Importantly, although iron and bortezomib sensitivity goes in
parallel, bortezomib-iron combination induced death of U266 and OPM-2, which are poorly sensitive
to individual treatments. Iron also potentiates the effect of carfilzomib, a second-generation drug
recently approved for MM treatment, suggesting that the beneficial effect of iron supplementation
might be generally applied to proteasome inhibitors-based treatments.
The finding that iron excess impairs proteasome activity reveals that mechanisms of iron toxicity
might not be limited to alteration of oxidative homeostasis. Ferrous iron impairs proteasomal
chymotrypsin-like activity of purified 26S particle and of MM cellular extracts in a dose-dependent
manner in vitro. The reversible inhibition of proteasome activity suggests that iron likely acts by steric
interference rather than by causing oxidative modifications. Iron impairs proteasome functionality also
in iron-exposed cells, as documented by iron-dependent accumulation of poly-Ub proteins. This event
occurs in highly iron sensitive cells, such as MM.1S and H929, likely facilitated by an unfavorable load
versus capacity ratio, as previously documented in MM.1S cells [15]. Differently, poly-Ub accumulation
does not occur in the relatively low iron sensitive U266 and OPM-2, in which the inhibitory effect of
iron on proteasome activity is likely buffered by a more favorable load versus capacity balance [15].
These data suggest that proteasome impairment is a determinant of iron toxicity, and that proteasome
levels contribute to define iron sensitivity. More importantly, the results indicate that reduction of
proteasome activity by iron cumulates that induced by bortezomib since poly-Ub protein accumulation
is greater than that induced by bortezomib as a single agent. The iron efficacy occurs in combination
with different proteasome inhibitors, as documented by experiments with MG132. In this context,
iron might be able to overcome the increased proteasome capacity, which occurs through increased
transcription and translation of proteasome subunits, a hallmark of bortezomib resistance [33].
As for the effect of iron on autophagy, the results obtained in MM cell lines exposed to increasing
iron doses suggest that iron does not directly influence autophagosome formation or autophagy
flux. Notwithstanding, autophagy stimulation might occur after iron exposure as a compensatory
mechanism of poly-Ub proteins accumulation, as it occurs in low proteasome capacity cells, such as
MM.1S. This event might limit iron toxicity when iron is combined with proteasome inhibitors since
autophagy-increase promoted by iron might potentiate that promoted by bortezomib, which is a
recognized mechanism of drug-resistance [16,17]. As expected, bortezomib increases autophagy. Still,
iron has limited, if any, effect on this process.
3.2. Iron Is a Potential Candidate for MM Combination Therapy
In this work, we demonstrate the value of exploiting iron toxicity in combination with a common
clinical protocol of MM therapy. This issue was not demonstrated in our previous work that exclusively
tested the proteasome inhibitor in combination with high-dose iron [9]. In view of translational
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applicability, here we also tested both the reduction of FeDe dose used in previous studies, and multiple
iron administrations. We added iron to the VMP regimen, a first-line therapy for newly diagnosed
patients, especially for those considered non-fit for intensive treatment and autologous stem cell
transplantation, as the elderly [34]. Iron increased VMP response and prolonged remission without
causing evident systemic toxicity, as documented by normal liver and kidney function tests.
To underscore the clinical relevance of our approach, it should be noted that VMP is typically
adjusted and/or dose-reduced based on patient age, disease stage, and comorbidities. The intensity
reduction often leads to suboptimal and incomplete responses that, according to our data, could be
improved by iron, without adding systemic toxicity. The dose of bortezomib we used (0.25 mg/Kg)
was equivalent to the human dose (0.75 mg/m2) administered to old and frail patients. Similarly,
iron dextran dose used in mice (100 mg/Kg), once converted to human dose, is within the range of
iron dosages (up to 20 mg/Kg) that may be used to treat iron-deficient patients in a single injection.
Since iron dextran, commonly used in preclinical studies, is rarely employed in clinical practice because
of potentially severe allergic reactions [35], we moved to FeCM as an alternative iron source that
we used in mice at 20 mg/Kg, the maximal iron dose advised in humans. This iron preparation is
largely used without evident toxicity in both absolute and functional iron deficiency [36–38], the latter
condition being common in MM patients.
Our results revealed the potential toxicity of VMP regimen for frail subjects, as denoted by high
mortality in old Vk*MYC mice before the end of programmed treatment in the VMP-Saline arms.
Irrespective of the specific sensitivity showed by the 2 different pools of mice, iron administration
increased VMP efficacy and fully prevented these adverse events in both the experiments. Considering
the need of balancing treatment efficacy with limiting side effects, overall our pre-clinical data validate
iron as a candidate for combination therapy with VMP.
4. Materials and Methods
4.1. Cell Culture
Human MM cell lines MM.1S, U266 and H929 were purchased from ATCC, OPM-2 cells were from
DSMZ-German Collection of Microorganisms and Cell Cultures. All cells were cultured in RPMI-1640
medium (Euroclone, Pero, Italy) supplemented with 10% fetal bovine serum (Thermo-Scientific,
Waltham, MA, USA), 2 mM L-glutamine, 100 U/mL penicillin and 100mg/mL streptomycin
(Sigma–Aldrich, St. Louis, MO, USA). Cells (1.5 × 106) were seeded at 5 × 105 cells/mL and grown
in presence or absence of 10 nM bortezomib (LC Laboratories, Woburn, MA, USA,) and/or 600 µM
ferric ammonium citrate (FeAC) (Sigma–Aldrich). Alternatively, bortezomib was replaced by 5 nM
carfilzomib (Amgen, Thousand Oaks, CA, USA). At indicated times, cells were collected, diluted 1:1
with trypan blue exclusion dye (Bio-Rad, Hercules, CA, USA) and counted using TC20™ Automated
Cell Counter (Bio-Rad). Cell pellets were then processed for malondialdehyde determination or
western blotting. In a second experimental setting, cells were grown in presence of titrated doses of
FeAC (100, 300 and 600 µM), and cell pellets processed for western blotting.
4.2. Lipid Peroxidation
Lipid peroxidation was determined using the Lipid Peroxidation Assay Kit (Sigma–Aldrich)
following manufacturer instructions. Malondialdehyde levels were quantified using the Victor 3
Multilabel Counter (Wallac, Perkin Elmer, Waltham, MA, USA) at 532 nm for excitation and 553 nm for
emission. Finally, results were normalized on cell count.
4.3. 26S peptidase Activity Measurements
Chymotryptic activity of purified 26S rabbit proteasome [39] was measured using the specific
fluorogenic substrate Suc-LLVY-amc (Bachem, Bubendorf, Switzerland) as already described [40].
Proteasomal chymotrypsin-like activity was assessed in MM cell extracts according to published
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methods [41]. Briefly, cells were centrifuged and pellets incubated in ice-cold extraction buffer (50 mM
Tris/HCl, pH 7.5, 1 mM DTT, 0.25 M sucrose, 5 mM MgCl2, 0.5 mM EDTA, 2 mM ATP, 0.025% digitonin)
for 5 min and extracts prepared by centrifugation for at 20.000 g for 30 min at 4 ◦C. The inhibitory
effects of iron were studied by pre-incubating 26S or cellular extracts with ferrous chloride or ferrous
sulfate for 5 min and by comparing the residual activity with that of corresponding control anions used
at the same molar concentration. Suc-LLVY-AMC was used at a final concentration of 100 µM in 20 mM
Tris-HCl, pH 7.5, 1mM ATP, 2 mM MgCl2, and 0.2% BSA. Reactions were started by adding an aliquot of
26S or cellular extract, and the fluorescence of released AMC (excitation, 380 nm; emission, 460 nm) was
monitored continuously at 37 ◦C with a Cary Eclipse spectrofluorometer (Varian, Santa Clara, CA, USA).
Assays were calibrated using standard solutions of the free fluorophore, and the reaction velocities
were calculated from the slopes of the initial linear portions of the curves. Substrate consumption
at the end of incubation never exceeded 1%. In cellular extracts, background activity (caused by
non-proteasomal degradation) was determined by addition of 2 µM epoxomicin (Enzo Life Science,
NY, USA) and subtracted from total chymotrypsin-like activity [42].
4.4. Mouse Studies
Mice were bred in the pathogen-free animal facility of the IRCCS Ospedale San Raffaele in
accordance with the European Union guidelines. The study was approved by the local Institutional
Animal Care and Use Committee and by the Italian Ministry of Health (225/2015-PR). Vk*MYC mice
(n: 22; monoclonal component > 7%) were treated with 0.25 mg/Kg bortezomib (i.p.) (Millennium
Pharmaceuticals, Cambridge, MA, USA) at days 1,4,8,11 plus 2 mg/Kg melphalan (i.p.) (Denza Join
Enterprise, Malaysia) and 20 mg/Kg prednisone (p.o.) (Caesar & Loretz GmbH, Hilden, Germany) at
days 1–4 (VMP cycle). We replicated VMP cycle after 7 weeks for a total of 3 times. A group of mice
(n = 11) was additionally treated with 100 mg/kg iron dextran (i.p.) (Sigma–Aldrich) at day 5 of every
cycle. We followed treatment response by measuring monoclonal component (M-spike) levels by serum
protein electrophoresis at days 21, 42, 70, 91, 119, 140 after treatment start. A second pool of Vk*MYC
mice (n: 30; monoclonal component > 7%) was treated with VMP as describe above, for 2 cycles.
A group of these mice (n = 15) was additionally treated with 20 mg/kg of ferric carboxymaltose (i.v.)
(Vifor Pharma, St. Gallen, Switzerland) at day 5 of every cycle. M-spike levels were measured at days
21, 42, 70, 91 after treatment start. Within each experimental setting, treatment groups were matched
for weight, age and disease level.
5. Conclusions
We report that iron exposure has multiple toxicities in MM cells, ultimately causing their death.
Iron generates oxidative stress and lipid damage and inhibits proteasome functionality, thus interfering
both with redox and protein homeostasis, essential processes for MM cell survival. These pre-clinical
results pave the way to design pilot clinical trials that include iron administration to increase the
efficacy of current MM therapies, such as VMP regimen. This approach might be tested in elderly
frail patients affected by multiple comorbidities who often have incomplete responses to VMP dose
reduction, and whose treatment still remains a major therapeutic challenge.
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samples of VK*MYC mice, Figure S5: Liver iron content of Vk*MYC mice, Figure S6: Ferric carboxymaltose
improves VMP regimen efficacy in Vk*MYC mice, Figure S7: Original uncropped blots of western blotting
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functionality; Flow cytometry of bone marrow samples; Analysis of liver iron content; Statistical analyses.
Author Contributions: J.B. contributed to the experimental design, performed research, analyzed results and
contributed to writing the manuscript. F.M. and F.C. performed research and analyzed results. P.C., C.C., and P.G.
contributed to the experimental design and to writing the manuscript. A.C. conceived the study, designed the
Cancers 2020, 12, 970 13 of 15
experimental work, analyzed results and wrote the manuscript. All authors have read and agreed to the published
version of the manuscript.
Funding: This work was partially supported by the Italian Association for Cancer Research (AIRC) Program
Grant in Molecular Oncology-Extension no. 9965 (to A.C.). J.B. was supported by FIRC-AIRC fellowship for Italy
id. 22496.
Acknowledgments: The authors thank Marta Chesi and P. Leif Bergsagel for providing the Vk*MYC mouse
model, Simona Malato for supplying ferric carboxymaltose, Isabella Fermo and Michele Raso for mouse sera
analysis and Giovanni Tonon for precious advice.
Conflicts of Interest: C.C. is a Vifor Pharma consultant, and member of the advisory board of Celgene and
Novartis. The other authors declare no potential conflicts of interests.
References
1. Gu, Z.; Wang, H.; Xia, J.; Yang, Y.; Jin, Z.; Xu, H.; Shi, J.; De Domenico, I.; Tricot, G.; Zhan, F. Decreased
ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015, 75, 2211–2221.
[CrossRef] [PubMed]
2. Tesfay, L.; Clausen, K.A.; Kim, J.W.; Hegde, P.; Wang, X.; Miller, L.D.; Deng, Z.; Blanchette, N.; Arvedson, T.;
Miranti, C.K.; et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015,
75, 2254–2263. [CrossRef] [PubMed]
3. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of
potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006,
103, 14901–14906. [CrossRef] [PubMed]
4. Kovacevic, Z.; Kalinowski, D.S.; Lovejoy, D.B.; Yu, Y.; Suryo Rahmanto, Y.; Sharpe, P.C.; Bernhardt, P.V.;
Richardson, D.R. The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Curr. Top.
Med. Chem. 2011, 11, 483–499. [CrossRef]
5. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to Tango: Regulation of Mammalian Iron
Metabolism. Cell 2010, 142, 24–38. [CrossRef]
6. Wang, J.; Pantopoulos, K. Regulation of cellular iron metabolism. Biochem. J. 2011, 434, 365–381. [CrossRef]
7. Breuer, W.; Shvartsman, M.; Cabantchik, Z.I. Intracellular labile iron. Int. J. Biochem. Cell Biol. 2008,
40, 350–354. [CrossRef]
8. Rajkumar, S.V.; Dimopoulos, M.A.; Palumbo, A.; Blade, J.; Merlini, G.; Mateos, M.V.; Kumar, S.; Hillengass, J.;
Kastritis, E.; Richardson, P.; et al. International Myeloma Working Group updated criteria for the diagnosis
of multiple myeloma. Lancet Oncol. 2014, 15, e538–e548. [CrossRef]
9. Bordini, J.; Galvan, S.; Ponzoni, M.; Bertilaccio, M.T.S.; Chesi, M.; Bergsagel, P.L.; Camaschella, C.;
Campanella, A. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib
effect in models of multiple myeloma. Leukemia 2017, 31, 967–970. [CrossRef]
10. Campanella, A.; Santambrogio, P.; Fontana, F.; Frenquelli, M.; Cenci, S.; Marcatti, M.; Sitia, R.; Tonon, G.;
Camaschella, C. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica
2013, 98, 971–979. [CrossRef]
11. Benbrook, D.M.; Long, A. Integration of autophagy, proteasomal degradation, unfolded protein response
and apoptosis. Exp. Oncol. 2012, 34, 286–297.
12. Suh, D.H.; Kim, M.-K.; Kim, H.S.; Chung, H.H.; Song, Y.S. Unfolded protein response to autophagy as a
promising druggable target for anticancer therapy. Ann. N. Y. Acad. Sci. 2012, 1271, 20–32. [CrossRef]
[PubMed]
13. Amm, I.; Sommer, T.; Wolf, D.H. Protein quality control and elimination of protein waste: The role of
the ubiquitin–proteasome system. Biochim. Biophys. Acta Mol. Cell Res. 2014, 1843, 182–196. [CrossRef]
[PubMed]
14. Meister, S.; Schubert, U.; Neubert, K.; Herrmann, K.; Burger, R.; Gramatzki, M.; Hahn, S.; Schreiber, S.;
Wilhelm, S.; Herrmann, M.; et al. Extensive immunoglobulin production sensitizes myeloma cells for
proteasome inhibition. Cancer Res. 2007, 67, 1783–1792. [CrossRef] [PubMed]
15. Bianchi, G.; Oliva, L.; Cascio, P.; Pengo, N.; Fontana, F.; Cerruti, F.; Orsi, A.; Pasqualetto, E.; Mezghrani, A.;
Calbi, V.; et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple
myeloma cells to proteasome inhibition. Blood 2009, 113, 3040–3049. [CrossRef] [PubMed]
Cancers 2020, 12, 970 14 of 15
16. Pengo, N.; Scolari, M.; Oliva, L.; Milan, E.; Mainoldi, F.; Raimondi, A.; Fagioli, C.; Merlini, A.; Mariani, E.;
Pasqualetto, E.; et al. Plasma cells require autophagy for sustainable immunoglobulin production.
Nat. Immunol. 2013, 14, 298–305. [CrossRef]
17. Kawaguchi, T.; Miyazawa, K.; Moriya, S.; Ohtomo, T.; Che, X.F.; Naito, M.; Itoh, M.; Tomoda, A. Combined
treatment with bortezomib plus bafilomycin A1enhances the cytocidal effect and induces endoplasmic
reticulum stress in U266 myeloma cells: Crosstalk among proteasome, autophagy-lysosome and ER stress.
Int. J. Oncol. 2011, 38, 643–654.
18. Chesi, M.; Matthews, G.M.; Garbitt, V.M.; Palmer, S.E.; Shortt, J.; Lefebure, M.; Stewart, A.K.; Johnstone, R.W.;
Bergsagel, P.L. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of
clinical efficacy. Blood 2012, 120, 376–385. [CrossRef]
19. Tu, B.P.; Weissman, J.S. Oxidative protein folding in eukaryotes: Mechanisms and consequences. J. Cell Biol.
2004, 164, 341–346. [CrossRef]
20. Cenci, S.; Sitia, R. Managing and exploiting stress in the antibody factory. FEBS Lett. 2007, 581, 3652–3657.
[CrossRef]
21. Shimizu, Y.; Hendershot, L.M. Oxidative Folding: Cellular Strategies for Dealing with the Resultant
Equimolar Production of Reactive Oxygen Species. Antioxid. Redox Signal. 2009, 11, 2317–2331. [CrossRef]
22. Malhotra, J.D.; Kaufman, R.J. Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Cycle or a
Double-Edged Sword? Antioxid. Redox Signal. 2007, 9, 2277–2294. [CrossRef] [PubMed]
23. Bordini, J.; Bertilaccio, M.T.S.; Ponzoni, M.; Fermo, I.; Chesi, M.; Bergsagel, P.L.; Camaschella, C.;
Campanella, A. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the
VK*MYC model of multiple myeloma. Haematologica 2015, 100, 534–841. [CrossRef] [PubMed]
24. Arosio, P.; Levi, S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and
oxidative damage. Biochim. Biophys. Acta Gen. Subj. 2010, 1800, 783–792. [CrossRef]
25. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.;
Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell
2012, 149, 1060–1072. [CrossRef] [PubMed]
26. Yang, W.S.; Sriramaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.;
Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014,
156, 317–331. [CrossRef] [PubMed]
27. Yang, W.S.; Stockwel, B.R. Synthetic Lethal Screening Identifies Compounds Activating IronDependent,
Nonapoptotic Cell Death in Oncogenic-RASHarboring Cancer Cells. Cell 2008, 15, 234–245.
28. Bridges, R.J.; Natale, N.R.; Patel, S.A. System xc-cystine/glutamate antiporter: An update on molecular
pharmacology and roles within the CNS. Br. J. Pharmacol. 2012, 165, 20–34. [CrossRef]
29. Conrad, M.; Angeli, J.P.F.; Vandenabeele, P.; Stockwell, B.R. Regulated necrosis: Disease relevance and
therapeutic opportunities. Nat. Rev. Drug Discov. 2016, 15, 348–366. [CrossRef]
30. Wu, D.; Chen, L. Ferroptosis: A novel cell death form will be a promising therapy target for diseases.
Acta Biochim. Biophys. Sin. 2015, 47, 857–859. [CrossRef]
31. Yu, Y.; Xie, Y.; Cao, L.; Yang, L.; Yang, M.; Lotze, M.T.; Zeh, H.J.; Kang, R.; Tang, D. The ferroptosis inducer
erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell. Oncol.
2015, 2, 1–7. [CrossRef]
32. Roh, J.L.; Kim, E.H.; Jang, H.J.; Park, J.Y.; Shin, D. Induction of ferroptotic cell death for overcoming cisplatin
resistance of head and neck cancer. Cancer Lett. 2016, 381, 96–103. [CrossRef]
33. Rückrich, T.; Kraus, M.; Gogel, J.; Beck, A.; Ovaa, H.; Verdoes, M.; Overkleeft, H.S.; Kalbacher, H.;
Driesse, C. Characterization of the ubiquitin—proteasome system in bortezomib-adapted cells. Leukemia
2009, 23, 1098–1105. [CrossRef]
34. Kumar, S.K.; Berdeja, J.G.; Niesvizky, R.; Lonial, S.; Laubach, J.P.; Hamadani, M.; Stewart, A.K.; Hari, P.;
Roy, V.; Vescio, R.; et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with
lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label
phase 1/2 study. Lancet Oncol. 2014, 15, 1503–1512. [CrossRef]
35. Camaschella, C. Iron-Deficiency Anemia. N. Engl. J. Med. 2015, 372, 1832–1843. [CrossRef] [PubMed]
36. Steinmetz, T.; Tschechne, B.; Harlin, O.; Klement, B.; Franzem, M.; Wamhoff, J.; Tesch, H.;
Rohrberg, R.; Marschner, N. Clinical experience with ferric carboxymaltose in the treatment of cancer-
and chemotherapy-associated anaemia. Ann. Oncol. 2013, 24, 475–482. [CrossRef] [PubMed]
Cancers 2020, 12, 970 15 of 15
37. Favrat, B.; Balck, K.; Breymann, C.; Hedenus, M.; Keller, T.; Mezzacasa, A.; Gasche, C. Evaluation of a single
dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled
study. PLoS ONE 2014, 9, 3–12. [CrossRef] [PubMed]
38. Toledano, A.; Luporsi, E.; Morere, J.F.; Scotté, F.; Laribi, K.; Barrière, J.; Huot-Marchand, P.; Duvillié, L.;
Concas, V.H.; Bugat, R. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological
malignancies in France. Support. Care Cancer 2016, 24, 67–75. [CrossRef]
39. Raule, M.; Cerruti, F.; Benaroudj, N.; Migotti, R.; Kikuchi, J.; Bachi, A.; Navon, A.; Dittmar, G.; Cascio, P.
PA28αβ Reduces Size and Increases Hydrophilicity of 20S Immunoproteasome Peptide Products. Chem. Biol.
2014, 21, 470–480. [CrossRef]
40. Cascio, P.; Goldberg, A.L. Preparation of Hybrid (19S-20S-PA28) Proteasome Complexes and Analysis of
Peptides Generated during Protein Degradation. Methods Enzymol. 2005, 398, 336–352.
41. Cerruti, F.; Martano, M.; Petterino, C.; Bollo, E.; Morello, E.; Bruno, R.; Buracco, P.; Cascio, P. Enhanced
Expression of Interferon-γ-Induced Antigen-Processing Machinery Components in a Spontaneously
Occurring Cancer. Neoplasia 2007, 9, 960–969. [CrossRef] [PubMed]
42. Raule, M.; Cerruti, F.; Cascio, P. Enhanced rate of degradation of basic proteins by 26S immunoproteasomes.
Biochim. Biophys. Acta Mol. Cell Res. 2014, 1843, 1942–1947. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
